• En
  • Ru
  • Kr
  • Jp
  • Cn
  • Fr
  • It
  • De
  • Sp
  • Pt
  • Tr
  • Pl
  • Ar
  • Ph
  • Id
  • Hi
  • Nl
  • Vi
  • Cs
  • Gr
  • Ro
  • Hu
  • Dk
  • He
  • Hr
  • Sr
  • Lv
Sign in Sign up
#Blockchain, #Healthcare All projects

Clintex: Transforming Health Together

Blockchain Powered Clinical Trial Management

stage Ended crowdsale


  • Employees19


man Neill Barron


Neill leads clinical design of the CTi platform, ensuring it meets real-world challenges for the pharmaceutical industry. With a BSc in Biotechnology and MSc in Pharamceutical Technology & Business, he has over 20 years’ broad clinical development experience through a blend of senior roles in clinical data management, data analytics, process improvement and clinical data monitoring.

man Brendan O’Mainnin


Brendan is a highly experienced project manager and business operations analyst with extensive experience in the financial, communications & marketing sectors. Successful with proven leadership skills, he enjoys working with people to solve problems. Brendan has had an interest in the blockchain space since 2013 and looks forward to utilising his expertise with the ClinTex team.

man Dr. Samandip Dhesi


Samandip is a physician with ongoing partnerships with the largest NHS Trust in the UK, managing a number of NHS funded initiatives and research projects. Through his NHS and academic connections, Samandip will set up and lead the ClinTex and Intellimed collaboration, deploying the CTi platform in academic research settings, demonstrating the value of CTi in clinical trials.

man Adrian W. Donoghue


With his experience in software sales, marketing and development, as well as proven record in cultivating opportunities into viable businesses across the pharmaceutical, telecoms and construction sectors, Adrian will develop essential the strategy and foundation to support the ClinTex business model and develop partnerships with the pharmaceutical industry, ensuring successful and sustainable growth.

man John McCabe


John holds a BA (Hons) in Business & Law and is a licenced solicitor in England, Wales and Ireland after being admitted into the Law Society of Ireland in 2013. John has been working in law for over ten years and has a keen interest in all things blockchain. He is excited to be bringing his focus to the cryptocurrency legal and regulatory landscape

Crowdsale details

Distribution of tokens
  • Crowdsale (50%)
  • Strategic Partner Private Sale (10%)
  • Management Team (10%)
  • Team Incentive (Milestone Based Structured Bonus Scheme) (10%)
  • Reserved for Advisors (4%)
  • Reserved for Pharma Industrial Trials (Testing) (3%)
  • Reserved for Referrals, Promotions & Bounty (3%)
  • Shareholders (10%)
Budget allocation
  • platform development (35%)
  • Clinical and analytic development (30%)
  • ClinTex Research Grants (2%)
  • Marketing & sales (15%)
  • Legal and accounting expenses (10%)
  • Operational expenses (8%)
Details Indicators
Token Symbol CLX
Full Token Name CLX Token
Crowdsale Start November 1st, 00:00 GMT+03:00
Crowdsale End Hard cap is reached or November 30th, 00:00 GMT+03:00
Crowdsale Hard Cap Fixed, $17000000
Crowdsale Soft Cap Yes, $4000000
Token type utility token
Incorporation Details ClinTex Ltd, 215/1, Old Bakery Street, Valletta VLT 1451, Malta Company Registration Number: C87282
Domain owner Individual

Cost of the token

1 token for 0.1 $

Price without discounts


The exact dates are to be announced. Please keep an eye on ClinTex CTi media channels and sign-up to the ClinTex mailing list to ensure you are up to date.

Accepted currency

  • Bitcoin
  • Ethereum

Rate the project

Estimate the project on a five-point scale or switch to the simple scale

Five-point scale Simple scale

Relevance of the problem and Market size

1 2 3 4 5

Product competitiveness

1 2 3 4 5

Founders, Team & Advisors

1 2 3 4 5

Budget allocation and roadmap

1 2 3 4 5

Token economy, Tokenization & Business model

1 2 3 4 5

Distribution & Lock up of tokens, Discounts for early buyers

1 2 3 4 5

Summary rate the project

1 2 3 4 5



What is ClinTex?

ClinTex is a solution provider to the pharmaceutical industry, providing predictive analytics and machine learning to new medicines development and the clinical trials process.

What is CTi?

CTi – Clinical Trials Intelligence, is a decentralised software solution that will lower the cost of new medicines and speed up their delivery to market for the people that need them. It will achieve this by making the clinical trials process faster, more efficient and more cost effective for pharmaceutical companies that engage in the research of new medicines for market.

Why does CTi need to be decentralised?

Audit trails are a required procedure and control for all clinical data. The FDA and other regulatory authorities need to be able to verify the quality and integrity of the data (FDA, 2017) and a pharmaceutical company must, in accordance with Good Clinical Practice (GCP), record all changes to the data, who made the changes, and when. A blockchain ledger is the perfect record keeping tool for this use case because it does exactly that.

Further to the immutable nature of the blockchain, having a secure complete recorded history of all our clinical data views stored on a blockchain allows for the creation and evolution of a decentralised clinical database, which CTi will use for powerful machine learning algorithms that will increase in potency over time, providing a powerful predictive tool for clinical trials that introduces hitherto untapped opportunities for efficiency and quality in the conduct of clinical research.

Smart contracts will also allow for the ability to perform the secure execution of contracts and payments based on triggers and milestones in the clinical data. For example, a payment to an investigator can be automatically triggered as pre-set milestones are reached based on data entered and, later verified by an outside system known as an oracle (in our case Chainlink). This allows for the removal of costly and slow intermediaries.

Are there any independent sources outlining the demand for the solution that ClinTex’s CTi’s will bring?

Yes, there have been many calls for this solution from academics and pharmaceutical industry insiders, both in the media - "Big Pharma Seeks DLT Solution for Drug Costs" and "Blockchain could be a game changer in medical clinical trials" and in academic papers, such as "Blockchain technology for improving clinical research quality" by Mehdi Benchoufi and Philippe Ravaud, and "How Blockchain Can Transform The Pharmaceutical And Healthcare Industries" by the phUSE Working Group.

Do you have any competitors that are centralised, and if so, what is stopping them from doing the same thing?

There are centralised vendors like Tibco, that develop visualisations for clinical trials. But their focus is restricted to discrete tasks in clinical trials (rather than the end to end coverage offered by the CTi platform). With CTi, ClinTex will be first to market in its delivery of predictive analytics and machine learning to new medicines development, and the first to bring the advantages of distributed ledger technology.

And what about all the other healthcare related blockchain projects?

There are many health related blockchain/DLT projects, however most appear to be advocating the use of a blockchain to store patient medical records. To the best of our knowledge, no one as of yet is tackling the problems in clinical trials that CTi will solve, both in terms of cost savings for big pharma and bringing life-saving treatments to patients sooner.

How does CTi store data?

In Phase 1, CTi’s data storage solution utilises a hybrid of on-chain data & off-chain data: On-chain: Data hashes (digital ‘fingerprint’ of the dataset) which points to the location of that data, off-chain: Raw clinical data & analytical data, algorithm performance & computations In the latter phases, we will move to a fully decentralised storage solution, using Storj as our decentralised storage provider.

Does CTi use a public or private blockchain?

CTi uses a hybrid of public and consortium blockchains in the platform. CLX tokens (ERC20) are used on the public Ethereum chain for access and inter-platform payments, while in the backend CTi uses a consortium chain based on Ethereum for data verification. In the latter phases, a second second token, CTX (ERC721) will be introduced as a data-carrier token in the consortium blockchain.

Is CTi open-source?

Although ClinTex will endeavour to share everything we can pre-TGE, the algorithms behind CTi’s AI and predictive analytics are proprietary and as such the platform cannot be open source.

Who will be your first customers? And when?

We expect to begin on-boarding clients from mid 2019. Our first clients will be pharmaceutical partners who will take part in the CTi trial period. Please see our roadmap for more details.

What will I use the CLX token for?

The CLX token is used for access to the CTi platform via a staking licence model through the CTi integrated wallet. There is no other payment gateway for access to CTi.
CLX will also be used for inter-platform payments in phase 3; reward payments to clinical data providers and third party clinical investigators.

What will drive demand for the CLX token in the future?

All CLX tokens that will ever exist will be created in the (Token Generation Event) TGE, and as ClinTex on-boards pharmaceutical clients and partners to the CTi platform, each client licence will remove those staked tokens from the circulating pool for the period of the licence.
This reducing pool of supply, combined with ClinTexs’ promotion and marketing through the launch of the seven CTi DApp’s, are the two main factors behind ClinTex’s expectation that CLX demand will experience expansive growth.

What is the period of each CTi licence?

6-month, 12-month and 18-month licence options will be available on CTi.

Your fully diluted market capitalization is $36.6m. Do you think there is room for the CLX market cap to significantly grow from this starting point?

The savings to the pharmaceutical industry represented by the ClinTex CTi proposition far, far exceed the potential CLX TGE fully diluted market cap, and as such we expect to see significant growth, driven by clear and significant demand.

As per our whitepaper, just a 1% average cost reduction across clinical trials running today would generate a saving of $3.5 billion across the industry (based on the averages above).

Have your existing, and will your future, smart contracts all be independently audited?

Of course!

When is the TGE?

The TGE is scheduled to take place in Q4 of this year, with the exact date to be confirmed. Please sign-up to our Newsletter to stay up to date.

Will there be a KYC process? Which nationalities are excluded?

All TGE Participants will be required to undergo a whitelist identification verification process, in line with globally accepted standards of AML/KYC regulation. For the time being, citizens of the USA are excluded although we are having our lawyers investigate this matter and it may change in the future.

Will there be a referral system?

Yes, where a TGE participant that refers another TGE participant, the referee will get a bonus of 5% of the CLX that the person they referred purchases.

What are the bonus’s in the TGE and TGE Presale?

All pre-sale participants will receive a 20% bonus. The public TGE will also have a 5% bonus, for the first 24 hours only.

Is there a lockup period for CLX tokens?

The pre-sale CLX tokens will come with a 2 month lock-up period. The main public TGE CLX tokens will have no lock-up period. The private sale token will be locked-up until 4 months after the TGE finish date.

Why is the soft-cap in the TGE $4 million but your hard-cap $17 million – what is represented in the difference between the two figures in what ClinTex can deliver?

The softcap represents the minimum amount that will allow us to deliver something meaningful for pharma. This will start with our three core DApps – CTi-OEM, CTi-CDV and CTi-PDA.

In such a scenario, we would most likely have to wait until enough revenue is generated from the core DApps to fund the further development of the next four planned DApps and the phase 3 decentralised clinical database.

A full hardcap reach at TGE would allow ClinTex to execute the entire roadmap with maximum efficiency, which as well as development, includes an extensive marketing campaign within the pharma industry , ultimately driving more and more value back to the CLX token.

How much are you raising in private sale vs the public sale, and what is the rationale behind it?

We have limited the private sale to 10% of the total CLX, which is considerably less than the industry standard at this time but we think this is the fairest distribution for the ecosystem, and will go towards ensuring that the economics of the CLX token are not damaged by excessive ‘insider’ discounts.

What is the legal status of this ICO and token? Is this an unregulated space?

The CTi Token Generation Event is being conducted under the Malta Financial Authority’s regulated ICO framework and its legal status has been fully audited under the Financial Instrument Test by our legal partner, Zerafa Advocates.

ClinTex have ensured full regulatory compliance in sofar as possible but we encourage all TGE participants to check with their local authority before taking part.

I notice you are accepting Binance Coin (BNB) in your TGE – do you have an official partnership with Binance?

ClinTex do not have an official partnership with Binance. However as supporters of Binance’s contribution to the cryptocurrency space, we are happy to endorse BNB and the Binance eco-system by accepting BNB in our TGE, along with BTC, ETH and NEO.

When will CLX be available to trade on exchanges?

ClinTex will endeavour to get CLX listed on major exchanges as soon as possible.